<DOC>
	<DOCNO>NCT02998151</DOCNO>
	<brief_summary>The aim study utilize neurophysiologic assessment , behavioral measure clinical measure assess much deficit associate Fragile X Syndrome pre-dose post-dose Acamprosate , lovastatin , minocycline placebo .</brief_summary>
	<brief_title>Single-Dose Acamprosate , Lovastatin , Minocycline Placebo Fragile X Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fragile X Syndrome</mesh_term>
	<mesh_term>Minocycline</mesh_term>
	<mesh_term>Lovastatin</mesh_term>
	<mesh_term>L 647318</mesh_term>
	<mesh_term>Dihydromevinolin</mesh_term>
	<mesh_term>Acamprosate</mesh_term>
	<criteria>Subjects age 1555 , FXS complete study entitle `` Mechanisms brain circuit underlie fragile X syndrome ( IRB # 20158425 ) . FXS define full FMR1 mutation ( &gt; 200 CGG repeat ) confirm genetic testing . General good health determine physical exam , medical history laboratory work . Subjects history intolerance acamprosate , lovastatin , minocycline exclude . Subjects also exclude take investigational drug within 3 month , history substance abuse dependence within 6 month , significant psychiatric CNS neurological disease unrelated FXS . Uncontrolled seizure impact EEG data anticonvulsant , barbiturate , lithium benzodiazepine exclusion ( within 5 halflives ) . Those take psychiatric medication must stable dos 4 week test . For female subject child bear potential , positive urine pregnancy test . Potential subject creatinine clearance &lt; 50 mL/min exclude . Identified medical issue , inability tolerate study procedure study drug per discretion Principal Investigator .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>